Abstract
Background
The combination of immunotherapy and chemotherapy can improve the survival of metastatic gastric cancer (MGC) patients based on checkmate 649 and Orential 16. The neutrophil-to-lymphocyte ratio (NLR) in the pretreatment period can be used as a prognostic indicator in patients receiving immune checkpoint inhibitors (ICIs) to treat different cancers. However, no study has yet explored the relationships between NLR changes during PD-1 treatment and patient survival.
Method
First, we enrolled patients diagnosed with MGC under anti-PD-1-based treatments from October 1st, 2015 to December 31st, 2020 at the Chinese PLA General Hospital. These patients were stratified regarding their baseline NLR and variants of NLR. Then we explored the association between relative NLR changes and other clinical features with the overall survival (OS) and progression-free survival (PFS) of patients treated with immunotherapy using multivariate Cox analysis.
Results
A total of 137 patients were enrolled in the present study. We categorized patients into decreased (ΔNLR < 0) and increased (ΔNLR ≥ 0) post-treatment NLR groups. The median OS and PFS were 12.3 months and 7.8 months for patients with ΔNLR < 0, respectively, compared to 7.5 months and 4.3 months for patients with ΔNLR ≥ 0 (both p < 0.05). The ORR was 41.8% in the ΔNLR < 0 group, higher than the ΔNLR ≥ 0 group (ORR = 24.3%). Patients with both NLR ≥ 3.23 and ΔNLR ≥ 0 had a significantly increased risk of death (HR: 2.349, 95% CI: 1.701 – 3.243, p < 0.001) and disease progression (HR: 2.297, 95% CI: 1.666 – 3.167, p < 0.001) compared to patients with NLR < 3.23 and ΔNLR < 0. Patients with either NLR ≥ 3.23 or ΔNLR ≥ 0 showed an intermediate risk of death (HR: 2.626, 95% CI: 1.660 – 4.155, p < 0.001) and progression (HR: 2.554, 95% CI: 1.590 – 4.101, p < 0.001). The ORR (50.0%) and DCR (91.2%) was higher in the NLR < 3.23 and ΔNLR < 0 group compared to other combination groups (both p < 0.05).
Conclusion
The combination of NLR changes after anti-PD-1 treatment with the baseline NLR was significantly correlated with patient survival and could be used to categorize patients into high- and low-risk groups. Finally, prospectively designed clinical trials are required to substantiate our current findings.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
1 Introduction
The addition of immunotherapy in the treatment of advanced gastric cancer can prolong the overall survival (OS) compared to chemotherapy [1], in which the survival time is poor with a median OS of less than one year [2]. According to checkmate 649, the combination of nivolumab with chemotherapy can have beneficial outcomes with PFS and OS regardless of Programmed cell death ligand 1 (PD-L1) expression [3]. However, not all patients can benefit from immunotherapy. Hence, the selection of biomarkers for predicting the efficacy of treatment or survival prognosis is of great interest. Well-recognized biomarkers include the expression of PD-L1 [4, 5], the tumor mutation burden (TMB) [6, 7], and microsatellite instability (MSI) [8]. However, these methods still have limitations.
Furthermore, system inflammation indexes (SII) such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in peripheral blood samples had been explored as biomarkers in various cancers treated with immunotherapy, including melanoma, esophagus cancer, non-small cell lung cancer (NSCLC), and renal cell cancer. Additionally, NLR changes were also found to be prognostic factors in retrospective studies of NSCLC [9] and renal cell carcinoma patients treated with ICIs. Previously, in patients with metastatic gastric cancer (MGC) in the third line of nivolumab monotherapy, NLR changes could be used to predict outcomes. Meanwhile, there are no reports exploring the prognosis value of dynamic changes on the NLR before and after Programmed cell death-1(PD-1) inhibitors were given in combination or as a monotherapy for patients with advanced or recurrent GC. Therefore, in the present study, we explored the prognostic value of NLR changes in MGC patients treated with PD-1 inhibitors.
2 Methods
2.1 Patients
We performed a retrospective analysis of patients diagnosed with metastatic gastric cancer (MGC) under anti-PD-1/PD-L1-based treatment regimens from October 1st, 2015 to December 31st, 2020 at the Chinese PLA General Hospital. Medical and pathological records were obtained from electric medical records. This study followed the Declaration of Helsinki and was approved by the Ethics Committee of the Chinese PLA General Hospital (No. S2019-200–01). The selection criteria included: confirmed pathologic diagnosis as adenocarcinoma gastric cancer; had at least one measurable lesion; received at least two cycles of anti-PD-1 inhibitor drugs besides anti-PD-L1 antibodies; had at least one imaging response assessment through the treatment period.
2.2 Data collection
The data collected included age, gender, PD-L1 expression status, Eastern Cooperative Oncology Group Performance Status (ECOG PS), tumor location, differentiation, metastasis organs, therapy line, and treatment regime. The complete blood count, including leukocytes, neutrophils, and lymphocytes, was evaluated before PD-1 inhibitor administration and after two cycles of PD-1-based treatment. The baseline NLR values were defined as the absolute neutrophil count divided by the absolute lymphocyte count at the beginning of the PD-1 treatment. The ΔNLR was defined as the difference between the NLR after two cycles of treatment and the baseline NLR. The anti-cancer response was also derived from medical data. Based on the Response Evaluation Criteria in Solid Tumor version 1.1, response states were classified into CR (complete response), PR (partial response), SD (stable disease), and PD (progression disease). The survival data, including the OS calculated from the first PD-1 inhibitor treatment until death or the last follow-up (censored), and the PFS derived from the first PD-1 inhibitor treatment until the first documented disease progression (PD), death, or the last follow-up (censored) was also retrieved.
2.3 Treatment regimen
Baseline characteristics of treatment regimens were divided into two parts: monotherapy or combination with chemotherapy. The type of PD-1 inhibitor was decided according to the physician’s choice and patient's willingness, which contain Pembrolizumab (200 mg), and nivolumab at a dose of 3 mg/kg, 200 mg sintilimab, or 240 mg toripalimab intravenously once every 3 weeks. The combination chemotherapy included oxaliplatin-based regimen or docetaxel-based with cisplatin or fluorouracil and other combinations. For treatment, all patients signed informed consent forms.
2.4 Patients groups
Considering the dynamic NLR changes, we classified patients into ΔNLR ≥ 0 or ΔNLR < 0 groups. To further explore the prognostic value of the combination of baseline NLR and ΔNLR, patients were also stratified into three groups regarding the baseline NLR cut-off (optimal cutoff of baseline NLR were 3.23 according to our previous study [10]) and ΔNLR ≥ 0; Group 1: NLR < 3.23 and ΔNLR < 0; Group 2: NLR ≥ 3.23 and ΔNLR < 0 or NLR < 3.23 and ΔNLR ≥ 0; Group 3: NLR ≥ 3.23 and ΔNLR ≥ 0.
2.5 Statistical analyses
Statistical analyses were performed using SPSS for Windows v 20.0 (SPSS, Inc., Chicago, IL). Differences in category variables among groups were compared by χ2 tests. The objective response rate (ORR) was defined as the number of CR plus PR/all populations, and the disease control rate (DCR) was defined as the number of CR + PR + SD/populations. Survival curves of PFS and OS were estimated by the Kaplan–Meier method. The log-rank test was used to compare OS and PFS between groups when the patients were stratified into different ΔNLR groups or different combination groups (baseline NLR and ΔNLR groups). Prognostic factors for OS and PFS were evaluated by multivariate analysis. The level of significance was set to p < 0.05.
3 Results
3.1 Patient characteristics
A total of 137 patients were enrolled in this study. The baseline NLR group (cutoff of 3.23) is presented in Table 1. Then, we categorized patients into decreased (ΔNLR < 0) and increased (ΔNLR ≥ 0) post-treatment NLR groups. Sixty-seven (48.9%) and 70 patients (50.1%) presented in t ΔNLR < 0 and ΔNLR ≥ 0, respectively. No significant differences were detected in baseline characteristics between baseline NLR or NLR change groups. The median OS and PFS of the whole population were 10.70 (95% CI: 8.67–12.72 months) and 5.20 months (95% CI: 3.75–6.64 months), respectively.
3.2 ΔNLR and survival
The median OS and PFS were 12.3 (95% CI: 10.7– 14.4 months) and 7.8 months (95% CI: 5.4–11.3 months) for patients with ΔNLR < 0, respectively, and 7.5 (95% CI: 4.6–8.7 months) and 4.3 months (95% CI: 3.0–4.7 months) for patients with ΔNLR ≥ 0, respectively (p = 0.012 for OS and p = 0.038 for PFS) (Figs. 1 and 2). The multivariate analysis showed that patients with ΔNLR ≥ 0 and receiving anti-PD-1 inhibitor in the second or further lines were significantly associated with worse PFS and OS (Table 2). Notably, increased NLR levels after treatment were independently associated with increased risk of death (HR = 1.615, 95% CI: 1.103–2.365, p = 0.014) and disease progression (HR = 1.466, 95% CI: 1.016–2.116, p = 0.041) (Table 3). Meanwhile, the ORR (41.8% vs. 24.3%) was higher in the decreased post-treatment NLR (ΔNLR < 0) group compared with the increased post-treatment NLR (ΔNLR ≥ 0) group (p = 0.045). On the other hand, there were no statistically difference regarding the DCR between the two groups (89.6% vs. 77.1%, p = 0.068) (Table 4).
3.3 Baseline NLR, ΔNLR, and survival
To further evaluate the prognostic value of the combination of baseline NLR and ΔNLR, patients were stratified based on baseline NLR and ΔNLR into three groups: 34 patients with NLR < 3.23 and ΔNLR < 0 (Group 1); 80 patients with either NLR ≥ 3.23 and ΔNLR < 0, or NLR < 3.23 and ΔNLR ≥ 0 (group 2); 23 patients with NLR ≥ 3.23 and ΔNLR ≥ 0 (group 3).
The median OS was 14.4 (95% CI: 13.6–21.9) versus 9.2 (95% CI: 7.8–13.7) versus 4.6 (95% CI: 4.3–6.3) months for patients in groups 1, 2, and 3, respectively (Fig. 3). Moreover, the median PFS was 10.4 (95% CI: 10.1–11.6) versus 5.1 (95% CI: 3.1–7.3) versus 2.2 (95% CI: 1.7–3.2) months (both p < 0.001), respectively (Fig. 4). The multivariate analysis showed that patients with elevated NLR and ΔNLR (group 3) had a significantly increased risk of death (HR: 2.349, 95% CI: 1.701 – 3.243, p < 0.001) and disease progression (HR: 2.297, 95% CI: 1.666 – 3.167, p < 0.001) compared to patients with NLR < 3.23 and ΔNLR < 0 (group 1) (Table 5). Patients with either NLR ≥ 3.23 and ΔNLR < 0 or NLR < 3.23 and ΔNLR ≥ 0 (group 2) showed an intermediate risk for both death (HR: 2.626, 95% CI: 1.660 – 4.155, p < 0.001) and disease progression (HR: 2.554, 95% CI: 1.590 – 4.101, p < 0.001) (Table 5). Detailed information of the multivariate analysis is provided in Table 3. The ORR for groups 1, 2, and 3 was 50.0, 28.8, and 21.7%, respectively (p = 0.040) and the DCR was 91.2, 85.0, and 65.2%, respectively (p = 0.029) (Table 4).
4 Discussion
Previous studies have demonstrated that changes in the NLR during nivolumab monotherapy were associated with GC survival, as well as combined with PD-1 inhibitor [11]. Here, we reported the prognostic value of baseline NLR and early NLR variations and its utility in MGC patients receiving anti-PD1 with different treatment combinations.
The relationship between high baseline NLR values and poor survival outcomes has been recognized for some tumors treated with checkmate inhibitors [12,13,14,15,16]. As reported in our center, the baseline NLR is associated with the survival of MGC patients using the anti-PD-1 drugs. The optimal cut-off of 3.23 was derived from our previous study [10]. Based on that cut-off value, we not only explored the NLR changes (ΔNLR) after two weeks of treatment but also the combined value of baseline NLR and ΔNLR.
We showed that the NLR increased after two cycles of anti-PD-1 treatment and was associated with worse outcomes. The NLR variations could be used to predict the OS and the PFS. High baseline NLR and increased post-treatment NLR were also independent factors of worsened survival outcomes. Furthermore, the combination of low baseline NLR and decreased post-treatment NLR was associated with higher ORR and DCR and especially favorable prognoses. Compared to current prognostic factors, such as the expression of PD-L1 [17] and TMB [18], routine lab tests are convenient and easy to monitor. Meanwhile, although PD-L1 or TMB are optimal candidate indicators as demonstrated by different clinical studies, they also presented controversial outcomes in some types of cancer [3, 5, 19, 20]. The inexpensive and readily available nature of the NLR allows it to be conveniently monitored over time. Additionally, in the present study, combining baseline NLR and NLR variants was better to stratify patients who might benefit from immunotherapy, consistent with the results reported for other types of cancer [11, 21,22,23]. Since inflammations are associated with tumor growth and progression, many inflammatory system markers are used as surrogates of systemic inflammatory response and as prognostic indicators [24,25,26,27]. However, the mechanisms by which NLR relates to ICI activity and OS remain unknown. An earlier report suggested associations between the NLR and the levels of pro-inflammatory cytokines and interleukin (IL)-6 that induce cancer progression, and GC patients with high levels of these cytokines exhibited poor prognoses [28,29,30].
Our current study also has some limitations. First, this was a retrospective single-center work and the sample size was small. Hence, external validation in a prospective study is required. Second, although we applied the cut-off value confirmed by our previous study [10], the optimal cut-off values for NLR remain unknown. Third, neither the expression of PD-L1 nor tumor mutation burden was analyzed in our clinical routine. So it is hard to provide these information of enrolled patients in the manuscript and compare your findings (ΔNLR) to these biomarkers in terms of sensitivity, specificity and outcome predictive capacity. Fourth, the mechanisms of action are unknown, and both neutrophil and lymphocyte number are sensitive to systemic nutrition, immune and infection status, further studies evaluating the relationship between NLR and tumor micro-environment, nutrition status, line of therapy, and immune-related adverse events might help delineate the mechanisms between baseline NLR and NLR changes and OS.
5 Conclusion
In summary, we showed that the changes in NLR in the early stages of different immunotherapies for MGC patients can be used to predict outcomes, especially combined with the baseline NLR. Finally, our current results might help clinicians decide whether to continue immunotherapy in MGC patients.
Availability of data and materials
Data available on request through any authors of this study.
Abbreviations
- OS:
-
Overall survival
- PD-L1:
-
Programmed cell death ligand 1
- TMB:
-
Tumor mutation burden
- MSI:
-
Microsatellite instability
- SII:
-
System inflammation indexes
- NLR:
-
Neutrophil-to-lymphocyte ratio
- PLR:
-
Platelet-to-lymphocyte ratio
- NSCLC:
-
Non-small cell lung cancer
- GC:
-
Gastric cancer
- PD-1:
-
Programmed cell death-1
- MGC:
-
Metastatic gastric cancer
- ECOG PS:
-
Eastern Cooperative Oncology Group Performance Status
- CR:
-
Complete response
- PR:
-
Partial response
- SD:
-
Stable disease
- PD:
-
Progression disease
References
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–7.
Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141–8.
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.
Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33.
Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–80.
Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–608.
Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–6.
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.
Khunger M, Patil PD, Khunger A, et al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE. 2018;13(10):e0197743.
Gou M, Qu T, Wang Z, et al. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 inhibitor survival in patients with metastatic gastric cancer. J Immunol Res. 2021;2021:2549295.
Ota Y, Takahari D, Suzuki T, et al. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol. 2020;85(2):265–72.
Cao W, Yao X, Cen D, Zhi Y, Zhu N, Xu L. The prognostic role of platelet-to-lymphocyte ratio on overall survival in gastric cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20(1):16.
Yamada T, Hayashi T, Inokuchi Y, et al. Impact of the neutrophil-to-lymphocyte ratio on the survival of patients with gastric cancer treated with nivolumab monotherapy. Target Oncol. 2020;15(3):317–25.
Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74.
Cassidy MR, Wolchok RE, Zheng J, et al. Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment. EBioMedicine. 2017;18:56–61.
Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 2018;11:955–65.
Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30(2):250–8.
Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30(9):1479–86.
McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–72.
Boku N, Ryu MH, Kato K, Chung HC, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30(2):250–8.
Chen S, Li R, Zhang Z, et al. Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors. Transl Lung Cancer Res. 2021;10(3):1397–407.
Simonaggio A, Elaidi R, Fournier L, et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother. 2020;69(12):2513–22.
Li M, Spakowicz D, Burkart J, et al. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J Cancer Res Clin Oncol. 2019;145(10):2541–6.
Xie X, Luo KJ, Hu Y, Wang JY, Chen J. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. Dis Esophagus. 2016;29(1):79–85.
Kim HS, Ku JH. Systemic inflammatory response based on neutrophil-to-lymphocyte ratio as a prognostic marker in bladder cancer. Dis Markers. 2016;2016:8345286.
Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(2):425–8.
Hirahara T, Arigami T, Yanagita S, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19(1):672.
Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56(6):782–9.
Ock CY, Nam AR, Lee J, et al. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer. 2017;20(2):254–62.
Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol. 2014;89(1):129–39.
Funding
This study was supported by the Key Research and Development Project of Hainan (grant no. ZDYF2023SHFZ117).
Ethics declarations
Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Chinese PLA General Hospital (No. S2019-200–01).
Consent for publication
All the authors consent for publication.
Competing interests
There have no conficts of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gou, M., Zhang, Y., Wang, Z. et al. Changes in the neutrophil-to-lymphocyte ratio (NLR) as predictive values for metastatic gastric cancer patients with PD-1 inhibitors. Holist Integ Oncol 3, 5 (2024). https://doi.org/10.1007/s44178-024-00074-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s44178-024-00074-z